FDA panel unanimously backs Eisai Alzheimer's drug; Teva, CVS, and others finalize opioid settlements

Taking stock of the drug industry, from the lab to the medicine chest

June 9, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA panel unanimously endorses Eisai's Alzheimer's drug The FDA panel voted 6-0 that a Leqembi trial confirmed its benefits for Alzheimer's patients, recommending the FDA give it full approval. By Adam Feuerstein and Damian Garde STAT+ | Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis "This money will be used statewide for recovery and relief" for people who need assistance, said Ohio Attorney General Dave Yost. By Ed Silverman STAT+ | Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy Even as other genetic therapies for sickle cell move closer to approval, CRISPR company Editas sees a commercial opportunity for its product. By Andrew Joseph Alex Hogan/STAT FDA's letter to medical device maker iRhythm is a warning for the industry The FDA issued a warning to medical device maker iRhythm for marketing its product for "high risk" patients. By Lizzy Lawrence STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | Updated data show long-term benefits of CRISPR treatment for sickle cell, beta thalassemia New results showed the one-time therapy helped people live free of pain and transfusions for over a year. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser